Acuitas Investments’s AN2 Therapeutics ANTX Stock Holding History

Acuitas Investments’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-445,783	Closed	-$477K	–	69
2024 Q3	$477K	Buy	+445,783	New	+$774K	0.21%	101

Other funds holding ANTX

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Acuitas Investments's ANTX Position: Q4 2024 in Review

Acuitas Investments sold out of AN2 Therapeutics (ANTX) in Q4 2024, closing a stake of 445,783 shares — an estimated $477K sold.

Acuitas Investments first reported a position in ANTX in Q3 2024 and held it in 1 quarter. The position peaked at $477K in Q3 2024. 37 funds tracked by Wall St. Rank hold ANTX as of Q4 2024.

Acuitas Investments reported no remaining AN2 Therapeutics position as of Q4 2024 after selling out during the quarter.
Acuitas Investments sold 445,783 AN2 Therapeutics shares in Q4 2024, an estimated $477K.
Acuitas Investments first reported a position in AN2 Therapeutics in Q3 2024 and held it in 1 quarter.
Acuitas Investments's AN2 Therapeutics position peaked at $477K in Q3 2024.
37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2024.

Based on Acuitas Investments's 13F filing for Q4 2024, filed 31 Jan 2025.